[go: up one dir, main page]

MX379265B - Aplicacion dérmica de toxina botulínica en nanoemulsiones para usarse en el tratamiento de trastornos de la piel. - Google Patents

Aplicacion dérmica de toxina botulínica en nanoemulsiones para usarse en el tratamiento de trastornos de la piel.

Info

Publication number
MX379265B
MX379265B MX2016000555A MX2016000555A MX379265B MX 379265 B MX379265 B MX 379265B MX 2016000555 A MX2016000555 A MX 2016000555A MX 2016000555 A MX2016000555 A MX 2016000555A MX 379265 B MX379265 B MX 379265B
Authority
MX
Mexico
Prior art keywords
nanoemulsions
dermal
methods
dermal delivery
chromhidrosis
Prior art date
Application number
MX2016000555A
Other languages
English (en)
Inventor
Boke Zhang
Jonathan Edelson
Timothy Kotyla
Original Assignee
Anterios Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anterios Inc filed Critical Anterios Inc
Publication of MX379265B publication Critical patent/MX379265B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216—Solid or semisolid forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/066—Multiple emulsions, e.g. water-in-oil-in-water
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/30—Characterized by the absence of a particular group of ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención describe sistemas y métodos para tratar trastornos y/o afecciones asociadas con el nivel dérmico de la piel. Tales trastornos incluyen acné, hiperhidrosis, bromhidrosis, cromhidrosis, rosácea, pérdida del cabello, infección dérmica y/o queratosis actínica. Los métodos involucran administrar nanoemulsiones (por ejemplo, composiciones de nanopartículas) que comprende al menos un agente terapéutico, tal como la toxina botulínica. En algunas modalidades, las nanoemulsiones se preparan, por ejemplo, mediante microfluidización a alta presión, y comprenden una distribución de tamaño de partícula exclusivamente entre 10 nm y 300 nm.
MX2016000555A 2008-06-26 2009-06-26 Aplicacion dérmica de toxina botulínica en nanoemulsiones para usarse en el tratamiento de trastornos de la piel. MX379265B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7606508P 2008-06-26 2008-06-26
PCT/US2009/048972 WO2009158687A1 (en) 2008-06-26 2009-06-26 Dermal delivery

Publications (1)

Publication Number Publication Date
MX379265B true MX379265B (es) 2025-03-11

Family

ID=41319550

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2010013562A MX2010013562A (es) 2008-06-26 2009-06-26 Aplicacion dermica.
MX2016000555A MX379265B (es) 2008-06-26 2009-06-26 Aplicacion dérmica de toxina botulínica en nanoemulsiones para usarse en el tratamiento de trastornos de la piel.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2010013562A MX2010013562A (es) 2008-06-26 2009-06-26 Aplicacion dermica.

Country Status (13)

Country Link
US (2) US20110212157A1 (es)
EP (2) EP2310000B1 (es)
JP (4) JP2011526302A (es)
KR (3) KR102080429B1 (es)
CN (2) CN102076333A (es)
AU (3) AU2009261995A1 (es)
BR (1) BRPI0914630A2 (es)
CA (2) CA3042777A1 (es)
ES (1) ES2761664T3 (es)
IL (1) IL209697B (es)
MX (2) MX2010013562A (es)
SG (1) SG10201608732VA (es)
WO (1) WO2009158687A1 (es)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130274837A1 (en) * 1998-10-23 2013-10-17 Babak Nemati Systems and Methods to Enhance Optical Transparency of Biological Tissues for Photobiomodulation
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9486408B2 (en) * 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
DK3184526T3 (en) 2005-12-13 2019-01-14 Incyte Holdings Corp PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS A JANUS-KINASE INHIBITOR
BRPI0719756A2 (pt) 2006-12-01 2014-01-21 Anterios Inc Nanopartículas de entidades anfifílicas
AU2007353340A1 (en) 2006-12-01 2008-11-20 Anterios, Inc. Peptide nanoparticles and uses therefor
WO2008151022A2 (en) 2007-05-31 2008-12-11 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
DK2740731T3 (en) 2007-06-13 2016-04-11 Incyte Holdings Corp CRYSTALLINE SALTS OF JANUSKINASEINHIBITOREN (R) -3- (4- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-CYCLOPENTYLPROPANNITRIL
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
WO2013009761A1 (en) 2011-07-13 2013-01-17 The Foundry, Llc Methods and apparatus for delivering a therapeutic agent to nasopharyngeal mucosa targets
US20100160368A1 (en) 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
LT2378876T (lt) 2008-12-19 2019-04-25 Medicis Pharmaceutical Corporation Mažesnio stiprumo dozės imikvimodo kompozicijos ir trumpi dozavimo režimai, skirti aktininės keratozės gydymui
CA2750233A1 (en) * 2009-01-28 2010-08-05 Nanobio Corporation Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof
WO2010092596A1 (en) * 2009-02-10 2010-08-19 Genepharm India Private Limited An oral pharmaceutical composition of dutasteride
WO2010125470A2 (en) 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
AU2010249443B2 (en) 2009-05-22 2015-08-13 Incyte Holdings Corporation 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as JAK inhibitors
MY156727A (en) 2009-05-22 2016-03-15 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EA025993B1 (ru) 2009-07-13 2017-02-28 Медисис Фармасьютикал Корпорейшн Композиции с более низким содержанием имиквимода и короткие режимы дозирования для лечения остроконечных и перианальных бородавок
CA2769625C (en) 2009-07-29 2017-04-11 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
AU2010302350B2 (en) 2009-10-02 2015-06-18 Journey Medical Corporation Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
AU2011224484A1 (en) 2010-03-10 2012-09-27 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US9066952B1 (en) * 2010-05-06 2015-06-30 Carolyn Brown Rejuvenating hair oil system and method of use
MY161078A (en) * 2010-05-21 2017-04-14 Incyte Holdings Corp Topical formulation for a jak inhibitor
CN106177940A (zh) 2010-05-26 2016-12-07 西莱克塔生物科技公司 含有佐剂的合成纳米载体的剂量选择
US8697041B2 (en) 2010-08-10 2014-04-15 Conopco, Inc. Anti-dandruff compositions with citrus fibers
US10758630B2 (en) * 2010-08-13 2020-09-01 The Johns Hopkins University Topical compositions and methods of detection and treatment
US20120039814A1 (en) * 2010-08-13 2012-02-16 Sample Jennifer L Topical Compositions and Methods of Detection and Treatment
US9994443B2 (en) 2010-11-05 2018-06-12 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
EP2640723A1 (en) 2010-11-19 2013-09-25 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
US8809307B2 (en) 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration
US11957753B2 (en) 2010-11-22 2024-04-16 Bausch Health Ireland Limited Pharmaceutical formulations containing corticosteroids for topical administration
US20130331768A1 (en) 2010-12-29 2013-12-12 Louis D. Nichamin Eye treatment
TR201905477T4 (tr) * 2011-01-24 2019-05-21 Anterios Inc Nano-parçacık bileşimler.
WO2012103040A1 (en) * 2011-01-24 2012-08-02 Anterios, Inc. Paraben compositions
US20120321579A1 (en) * 2011-01-24 2012-12-20 Anterios, Inc. Surfactant compositions
SG10201804552WA (en) * 2011-01-24 2018-07-30 Anterios Inc Nanoparticle compositions, formulations thereof, and uses therefor
US20120328549A1 (en) 2011-01-24 2012-12-27 Anterios, Inc. Oil compositions
JP6131194B2 (ja) * 2011-01-24 2017-05-17 アンテリオス， インコーポレイテッド 皮膚科学的症状を処置するためのエンプティナノ粒子組成物およびその使用
JP5964866B2 (ja) * 2011-03-02 2016-08-03 ピベッド リミテッド 過酸化水素と、長鎖アルコールのナノエマルジョンとを有する化学組成物
US20130123647A1 (en) 2011-05-03 2013-05-16 The Research Foundation Of State University Of New York Methods Useful in Optimizing the Treatment of Neuropathies and Targeting Tissues with Cosmetic Botulinum Injections
WO2012170866A1 (en) * 2011-06-10 2012-12-13 Norac Pharma Benzoyl peroxide microparticle process
KR20140040819A (ko) 2011-06-20 2014-04-03 인사이트 코포레이션 Ｊａｋ 저해제로서의 아제티디닐 페닐, 피리딜 또는 피라지닐 카르복스아미드 유도체
US9050337B2 (en) 2011-06-27 2015-06-09 Sang Duck Kim Method for treating atrophic skin scars using a mixture of botulinum toxin and air
AU2012283968B2 (en) * 2011-07-20 2016-04-14 Allergan, Inc. Botulinum toxins for use in a method for treatment of adipose deposits
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CN102349994B (zh) * 2011-10-21 2014-06-04 深圳市巨方生物技术有限公司 一种鳄鱼油生发乳及其制备方法
UA111867C2 (uk) * 2011-11-11 2016-06-24 Аллерган, Інк. ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ І СПОСІБ ЗАСТОСУВАННЯ ПОХІДНИХ 4-ПРЕГНЕН-11β-17-21-ТРІОЛ-3,20-ДІОНУ
US8697146B2 (en) * 2011-11-28 2014-04-15 A66 Incorporated Poly-hapten with topical hormone alopecia hair regrowth system
CN102429913B (zh) * 2011-12-13 2013-04-10 江苏圣宝罗药业有限公司 复方丙酸氯倍他索脂质体及其制剂
US20130224268A1 (en) * 2012-02-27 2013-08-29 Newgen Biopharma Corp. Topical delivery of hormonal and non hormonal nano formulations, methods of making and using the same
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
WO2013173720A1 (en) 2012-05-18 2013-11-21 Incyte Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2014012117A1 (en) * 2012-07-13 2014-01-16 South Dakota State University Compositions and methods for localized drug delivery through mammary papillae
CN102895245A (zh) * 2012-10-30 2013-01-30 河南牧翔动物药业有限公司 一种复方甲氧苄啶与盐酸多西环素纳米乳制剂及其制备方法
WO2014074147A1 (en) 2012-11-12 2014-05-15 Hollister Incorporated Intermittent catheter assembly and kit
LT3441092T (lt) 2012-11-14 2020-04-10 Hollister Incorporated Vienkartinis kateteris su slektyviai skaidoma vidine šerdimi
PH12020551186B1 (en) 2012-11-15 2024-03-20 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
WO2014100019A1 (en) * 2012-12-18 2014-06-26 Allergan, Inc. Prophylactic treatment of herpes recurrence
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
EP3712142B1 (en) 2013-01-11 2022-07-06 Corsair Pharma, Inc. Prodrugs of treprostinil
JP6067036B2 (ja) * 2013-01-31 2017-01-25 富士フイルム株式会社 乳化組成物
JP6397831B2 (ja) 2013-03-06 2018-09-26 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤の製造方法及びその中間体
US20140322428A1 (en) 2013-03-15 2014-10-30 Leading Edge Innovations, LLC Compositions having an oil-in-water dispersion of submicron particles to enhance foods and beverages
JP6360881B2 (ja) 2013-03-22 2018-07-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 触媒的ｍｔｏｒｃ１／２阻害薬及びオーロラａキナーゼの選択的阻害薬の組合せ
WO2014160628A2 (en) * 2013-03-25 2014-10-02 Sloan-Kettering Institute For Cancer Research Articles and methods for preventing and treating dermatologic adverse events
WO2014197008A1 (en) * 2013-06-03 2014-12-11 Huiwen Liu Compounds encapsulated nanoparticles and nanoemulsions preparation and use thereof
KR20160045081A (ko) 2013-08-07 2016-04-26 인사이트 코포레이션 Jak1 억제제용 지속 방출 복용 형태
WO2015066717A1 (en) 2013-11-04 2015-05-07 BioPharmX, Inc. Dosage form comprising an active ingredient and a plurality of solid porous microcarriers
WO2015069843A2 (en) 2013-11-08 2015-05-14 Hollister Incorporated Oleophilic lubricated catheters
MX2016005820A (es) * 2013-11-12 2016-08-11 Colgate Palmolive Co Metodos de seleccionado para antitranspirantes.
WO2015089178A1 (en) 2013-12-12 2015-06-18 Hollister Incorporated Flushable disintegration catheter
WO2015089197A2 (en) 2013-12-12 2015-06-18 Hollister Incorporated Flushable catheters
US10463833B2 (en) 2013-12-12 2019-11-05 Hollister Incorporated Flushable catheters
US10426918B2 (en) 2013-12-12 2019-10-01 Hollister Incorporated Flushable catheters
JP2017502090A (ja) * 2014-01-10 2017-01-19 セバシア，インコーポレイテッド 皮膚科用途のエネルギー吸収物質を含む組成物の使用のための治療間隔
ES2542088B1 (es) * 2014-01-29 2016-05-05 Enoc Solutions, S.L. Composición de azufre liposomado
EP3137055A4 (en) * 2014-05-01 2017-12-06 Anterios, Inc. Demonstrable efficacy across or within patient populations
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
JP6541158B2 (ja) * 2014-06-04 2019-07-10 国立大学法人大阪大学 粘膜ワクチン用アジュバント
US9364413B2 (en) * 2014-07-31 2016-06-14 Umo International Co., Ltd. Method for anti-aging treatment by surfactin in cosmetics via enhancing sirtuin
AU2016224863A1 (en) 2015-02-25 2017-10-12 Sun Pharma Advanced Research Company Ltd Nanoparticulate composition
WO2016205383A1 (en) 2015-06-17 2016-12-22 Hollister Incorporated Selectively water disintegrable materials and catheters made of such materials
LT3310389T (lt) 2015-06-18 2020-11-10 Bausch Health Ireland Limited Vietinio vartojimo kompozicijos, apimančios kortikosteroidą ir retinoidą, skirtos psoriazės gydymui
RU2018113280A (ru) 2015-09-16 2019-10-16 ДиЭфБи СОРИА, ЭлЭлСи Доставка наночастиц лекарственного средства и способы их использования
WO2017176380A1 (en) * 2016-02-22 2017-10-12 The General Hospital Corporation Systems and methods for selective targeting of structural features in treating skin conditions
JP7038674B2 (ja) 2016-06-09 2022-03-18 アーケマ・インコーポレイテッド 有機ペルオキシド分散体
US10463601B1 (en) * 2016-06-17 2019-11-05 Lorita Dillon Topical cosmetic composition
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
RU2762607C2 (ru) 2016-09-13 2021-12-21 Аллерган, Инк. Стабилизированные небелковые композиции клостридиального токсина
CN106265164B (zh) * 2016-09-20 2017-08-11 珠海市丝域化妆品有限公司 具有生发、头皮修护、保湿功效的组合物及其制备方法
KR102487144B1 (ko) * 2016-11-21 2023-01-12 에이리온 테라퓨틱스, 인코포레이티드 큰 물질의 경피 전달
KR101977456B1 (ko) * 2017-02-22 2019-05-10 한윤섭 모발의 육모를 촉진하고 탈모를 예방하는 화장료 조성물
EP3595633B1 (en) 2017-03-15 2023-07-05 DFB Soria, LLC Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes
JP6450999B2 (ja) * 2017-03-31 2019-01-16 国立大学法人群馬大学 Ｂ型ボツリヌス毒素を用いたレイノー現象の治療
WO2018208530A1 (en) * 2017-05-07 2018-11-15 Locus Ip Company, Llc Cosmetic compositions for skin health and methods of using same
US11311482B2 (en) 2017-05-12 2022-04-26 Bausch Health Us, Llc Topical compositions and methods for treating skin diseases
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
WO2018236873A1 (en) * 2017-06-19 2018-12-27 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
WO2019055880A2 (en) 2017-09-15 2019-03-21 Ampersand Biopharmaceuticals, Inc. METHOD OF ADMINISTRATION AND TREATMENT
CN109893473B (zh) * 2017-12-08 2022-07-26 苏珍仪 海洋深层浓缩物皮肤护理保养套组及其应用
US10987288B2 (en) 2017-12-08 2021-04-27 Yin-Ming Lo Deep-sea water concentrate skin application kit and use thereof
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
CN107951750B (zh) * 2017-12-14 2021-04-06 广东省保化检测中心有限公司 防晒组合物、防晒产品及防晒产品的制备方法
CN112105608B (zh) 2018-01-30 2023-07-14 因赛特公司 制备(1-(3-氟-2-(三氟甲基)异烟碱基)哌啶-4-酮)的方法
JP7372252B2 (ja) 2018-03-16 2023-10-31 ディーエフビー ソリア リミテッド ライアビリティ カンパニー タキサンのナノ粒子を用いる子宮頸部上皮内腫瘍（ｃｉｎ）および子宮頸癌の処置のための局所療法
SMT202400306T1 (it) 2018-03-30 2024-09-16 Incyte Corp Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak.
WO2019227034A1 (en) 2018-05-25 2019-11-28 Locus Ip Company, Llc Therapeutic compositions for enhanced healing of wounds and scars
AU2019281888B2 (en) 2018-06-04 2024-05-02 Arcutis Biotherapeutics, Inc. Method and formulation for improving roflumilast skin penetration lag time
AU2019284621B2 (en) * 2018-06-13 2025-02-27 Dermata Therapeutics, Inc. Compositions for the treatment of skin conditions
GB201810923D0 (en) * 2018-07-03 2018-08-15 Blueberry Therapeutics Ltd Compositions and method of treatment
AU2019312562B2 (en) 2018-07-30 2025-05-01 Curology, Inc. Compositions and methods of treating acne and photoaging
US11819504B2 (en) 2018-08-26 2023-11-21 Attain Health Inc. Methods and compositions to increase hair growth and/or prevent hair loss
JP2021535925A (ja) 2018-09-13 2021-12-23 エイリオン セラピューティクス， インコーポレイテッド プラスミノーゲンアクチベーターインヒビター１（ｐｌａｓｍｉｎｏｇｅｎ ａｃｔｉｖａｔｏｒ ｉｎｈｉｂｉｔｏｒ １）（ＰＡＩ−１）阻害剤（ｉｎｈｉｂｉｔｏｒ）およびその使用
AU2019339488B2 (en) 2018-09-13 2025-07-10 Eirion Therapeutics, Inc. Uses of plasminogen activator inhibitor 1 (PAI-1) inhibitors
KR101968873B1 (ko) * 2018-09-21 2019-04-29 아이큐어 주식회사 세포 침투 효과가 우수한 보툴리늄 유래 펩타이드를 포함하는 화장료 조성물
WO2020117564A1 (en) * 2018-12-03 2020-06-11 Eirion Therapeutics, Inc. Improved delivery of large agents
WO2020123312A1 (en) 2018-12-09 2020-06-18 Weinberg Assa Method to prevent and treat macular degeneration by vasodilators
CN111743852B (zh) * 2019-03-29 2022-10-28 傅柏舜 使大分子药物经皮肤通透的组合物
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
EP4236972A4 (en) * 2020-10-27 2024-11-20 Leading Edge Innovations, LLC System, method, and composition for skin improvement and transient flora reduction
MX2023006602A (es) 2020-12-04 2023-08-07 Arcutis Biotherapeutics Inc Formulación tópica de roflumilast que tiene propiedades antimicoticas.
WO2022150594A1 (en) * 2021-01-08 2022-07-14 Oregon State University Plant cuticle supplements as methods and use thereof
WO2022164804A1 (en) * 2021-01-26 2022-08-04 Nutraceutical Wellness Inc. Nano- or micro-emulsion compositions and methods of use thereof
CA3217338A1 (en) * 2021-04-30 2022-11-03 Noon Aesthetics M.R Ltd. Topical formulations comprising benzoyl peroxide and azelaic acid, and use thereof
WO2023287726A1 (en) 2021-07-12 2023-01-19 Penland Foundation Treatment of cancer using botulinum toxin and nitrous oxide
WO2023129215A1 (en) 2021-12-28 2023-07-06 Arcutis Biotherapeutics, Inc. Topical roflumilast aerosol foams
CN115429708B (zh) * 2021-12-31 2023-09-19 中国科学院过程工程研究所 一种兼具头皮养护与发丝滋养功效的护发素及其制备方法
US20230372233A1 (en) * 2022-05-23 2023-11-23 Mirparm LLC Composition and methods for hair regrowth
CN115089594A (zh) * 2022-06-20 2022-09-23 苏州大学 一种纳米乳剂及其制备方法和应用
KR20250057103A (ko) 2022-09-15 2025-04-28 아큐티스 바이오테라퓨틱스, 인크. 로플루밀라스트 및 많은 양의 약물을 용해시킬 수 있는 용매의 약학 조성물
KR102666469B1 (ko) 2023-05-04 2024-05-17 주식회사 아리바이오 텔로머라제 활성화제와 나노 입자를 포함하는 약물 전달용 조성물 및 이를 포함하는 탈모 예방, 개선 또는 치료용 조성물
KR102666470B1 (ko) 2023-05-04 2024-05-17 주식회사 아리바이오 텔로머라제 활성화제와 나노 입자를 포함하는 약물 전달용 조성물 및 이를 포함하는 탈모 예방, 개선 또는 치료용 조성물
US20250017855A1 (en) * 2023-07-14 2025-01-16 Institute of Advanced Sciences Pharmaceutical Preparation for Topical Delivery of Botulinum Toxin
KR102647264B1 (ko) 2023-11-01 2024-03-14 주식회사 아리바이오 텔로머라제 활성화제와 나노 입자를 포함하는 약물 전달용 조성물 및 이를 포함하는 탈모 예방, 개선 또는 치료용 조성물

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US296006A (en) 1884-04-01 John hoefleb
US3725540A (en) * 1970-07-30 1973-04-03 Procter & Gamble Color and odor stabilized dry aerosol antiperspirant
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4908154A (en) 1981-04-17 1990-03-13 Biotechnology Development Corporation Method of forming a microemulsion
US4533254A (en) 1981-04-17 1985-08-06 Biotechnology Development Corporation Apparatus for forming emulsions
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5651991A (en) * 1987-10-28 1997-07-29 Nippon Shinyaku Co. Ltd. Drug carriers
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5401243A (en) * 1990-08-21 1995-03-28 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US6165500A (en) 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
US5652274A (en) * 1991-03-01 1997-07-29 Martin; Alain Therapeutic-wound healing compositions and methods for preparing and using same
AU664827B2 (en) * 1991-05-03 1995-12-07 Raisio Benecol Ltd. A substance for lowering high cholesterol level in serum and a method for preparing the same
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US7384918B2 (en) * 1991-09-24 2008-06-10 Allergan, Inc. Botulinum toxin for treating muscle contracture
US6939852B2 (en) 1991-09-24 2005-09-06 Allergan, Inc. Methods and compositions for the treatment of cerebral palsy
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US6010715A (en) * 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1261849B (it) 1993-09-02 1996-06-03 Avantgarde Spa Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici.
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US8187612B2 (en) * 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5629021A (en) * 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
FR2730932B1 (fr) * 1995-02-27 1997-04-04 Oreal Nanoemulsion transparente a base de lipides amphiphiles non-ioniques fluides et utilisation en cosmetique ou en dermopharmacie
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
WO1996039167A1 (en) * 1995-06-06 1996-12-12 Pearce L Bruce Improved compositions and methods for chemodenervation using neurotoxins
US6002961A (en) 1995-07-25 1999-12-14 Massachusetts Institute Of Technology Transdermal protein delivery using low-frequency sonophoresis
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
JPH10114648A (ja) * 1996-10-11 1998-05-06 Kao Corp 皮膚外用組成物
AU731832B2 (en) * 1996-11-12 2001-04-05 Tamarkin Pharmaceutical Innovation Ltd Method for treatment of dermatological disorders
FR2755854B1 (fr) * 1996-11-15 1998-12-24 Oreal Nanoemulsion a base de lipides amphiphiles non-ioniques et cationiques et utilisations
FR2760970B1 (fr) * 1997-03-18 2000-03-10 Oreal Nanoemulsions a base de lipides amphiphiles non-ioniques et de silicones aminees et utilisations
GB9708066D0 (en) * 1997-04-22 1997-06-11 Woolcombers Group Plc Compositions and their use
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
EP1475099B2 (en) * 1997-07-15 2014-04-09 The Regents of the University of Colorado Use of botulinum toxin to treat urinary incontinence
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US5965154A (en) 1998-03-17 1999-10-12 Plc Holding, L.L.C. Adhesive matrix type transdermal patch and method of manufacturing same
DE59914485D1 (de) * 1998-03-30 2007-10-18 Mibelle Ag Cosmetics Verwendung von Nanoemulsionen zur Bestimmung der Biokompatibilität von lipophilen Stoffen im Zellkultur-Test und dafür geeignete Nanoemulsionen
FI111513B (fi) * 1998-05-06 2003-08-15 Raisio Benecol Oy Uudet fytosteroli- ja fytostanolirasvahappoesterikoostumukset, niitä sisältävät tuotteet sekä menetelmät niiden valmistamiseksi
US6242001B1 (en) * 1998-11-30 2001-06-05 Mcneil-Ppc, Inc. Method for producing dispersible sterol and stanol compounds
DE19856897A1 (de) * 1998-12-10 2000-06-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum zur Unterdrückung von Schnarchgeräuschen
FR2788007B1 (fr) * 1999-01-05 2001-02-09 Oreal Nanoemulsion a base de copolymeres blocs d'oxyde d'ethylene et d'oxyde de propylene, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
MXPA01007173A (es) * 1999-01-14 2002-04-15 Amcol International Corp Composiciones para liberacion controlada mejoradas y metodo.
US6635676B2 (en) * 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
WO2001001962A1 (en) * 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
US6358917B1 (en) * 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US7838008B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US6898427B1 (en) * 1999-12-29 2005-05-24 Bellsouth Intellectual Property Corporation Method of coupling portable communications device to first network by way of second network
FR2804015B1 (fr) * 2000-01-21 2005-12-23 Oreal Nanoemulsion contenant des lipides amphiphiles et un polymere non ionique et utilisations
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
FR2811561B1 (fr) * 2000-07-13 2003-03-21 Oreal Composition, notamment cosmetique, renfermant la dhea et/ou un precurseur ou derive chimique ou biologique de celle-ci, et un inhibiteur de metalloproteinase
FR2816949B1 (fr) * 2000-11-17 2003-11-28 Centre Nat Rech Scient Copolymere a structure sequencee compose d'un segment saccharidique lie a au moins un segment hydrophobe bioerodable, et particules correspondantes
SI1345597T1 (sl) * 2000-12-27 2007-12-31 Ares Trading Sa Amfifilni lipidni nanodelci za vgradnjo peptidov in/ali proteinov
FR2819427B1 (fr) * 2001-01-18 2003-04-11 Oreal Nanoemulsion translucide, son procede de fabrication et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
US20040048836A1 (en) * 2001-03-23 2004-03-11 Wilmott James M Method for preparing high pressure/ high shear dispersions containing physiologically active ingredients
US20020157819A1 (en) * 2001-04-04 2002-10-31 Julian Norley Graphite-based thermal dissipation component
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
KR100566911B1 (ko) * 2001-06-25 2006-04-03 주식회사 삼양사 약물 전달체용 음이온기-함유 양친성 블록 공중합체 및 그의 양이온성 약물과의 복합체
WO2003011333A1 (en) * 2001-07-27 2003-02-13 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Botulinum toxin in the treatment or prevention of acne
US7063860B2 (en) * 2001-08-13 2006-06-20 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
DE10146647A1 (de) * 2001-09-21 2003-04-24 Marc Heckmann Arzneimittel zur Prophylaxe und Therapie von Bromhidrosis
US20040224012A1 (en) 2001-10-05 2004-11-11 Pichit Suvanprakorn Topical application and methods for administration of active agents using liposome macro-beads
US20030077240A1 (en) * 2001-10-24 2003-04-24 Clariant International, Ltd. Use of high-purity phenylsilsesquioxane liquids for the preparation of cosmetic and pharmaceutical compositions
US7235230B2 (en) * 2001-10-24 2007-06-26 Clariant Finance (Bvi) Limited Leave-on compositions for personal care
KR20040062602A (ko) * 2001-10-30 2004-07-07 펜타팜아게 피부약학적 및 화장품학적 활성 올리고펩타이드
US20030113349A1 (en) * 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US6765001B2 (en) * 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
KR100441167B1 (ko) * 2001-12-27 2004-07-21 씨제이 주식회사 마이크로에멀젼 예비 농축액 조성물
US6861066B2 (en) * 2002-03-11 2005-03-01 Health Plus International Inc. Method for the delivery of a biologically active agent
US6688311B2 (en) * 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
US20040115159A1 (en) * 2002-03-29 2004-06-17 Tadlock Charles C Novel nanoemulsions
US7459164B2 (en) * 2002-05-28 2008-12-02 Botulinum Toxin Research Associates, Inc. Composition for therapeutic and cosmetic botulinum toxin
JP2005531606A (ja) * 2002-06-10 2005-10-20 エラン ファーマ インターナショナル，リミティド ナノ粒子ステロール製剤およびステロールの組合せ
US6996748B2 (en) * 2002-06-29 2006-02-07 Intel Corporation Handling faults associated with operation of guest software in the virtual-machine architecture
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
AU2003270575A1 (en) * 2002-09-12 2004-04-30 3M Innovative Properties Company Fluoroelastomers having low temperature characteristics and solvent resistance
US20040115727A1 (en) * 2002-12-11 2004-06-17 Allergan, Inc., A Corporation Evolved clostridial toxins with altered protease specificity
WO2004071538A2 (en) * 2003-02-05 2004-08-26 Amphora Discovery Corporation Topical delivery of cosmetic agents
US20060153876A1 (en) * 2003-02-24 2006-07-13 Ira Sanders Cell membrane translocation of regulated snare inhibitors, compositions therefor, and methods for treatment of disease
US20050079228A1 (en) * 2003-05-30 2005-04-14 Ashish Jaiswal Clear, stable topical compositions of clarithromycin and processes for their preparation
AU2004273779B2 (en) * 2003-06-04 2009-10-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof
WO2004112821A1 (ja) * 2003-06-20 2004-12-29 Santen Pharmaceutical Co., Ltd. 筋緊張亢進性疾患の治療剤
AU2004263136A1 (en) * 2003-08-08 2005-02-17 Barnes-Jewish Hospital Emulsion particles for imaging and therapy and methods of use thereof
US7419996B2 (en) * 2003-08-13 2008-09-02 The University Of Houston Parenteral and oral formulations of benzimidazoles
CH715855B1 (de) * 2003-08-28 2020-08-14 Mibelle Ag Zubereitung bestehend aus mindestens zwei Nanoemulsionen.
DE602004027936D1 (de) * 2003-10-29 2010-08-12 Sonus Pharmaceutical Inc Tocopherolmodifizierte therapeutische arzneimittelverbindung
KR101045658B1 (ko) * 2003-11-17 2011-07-01 쎄데르마 테트라펩티드 및 트리펩티드 혼합물을 포함하는 조성물
US20050136024A1 (en) * 2003-12-22 2005-06-23 Stockel Richard F. Dermatological compositions
US6974579B2 (en) * 2004-01-08 2005-12-13 Allergan, Inc. Methods for treating vascular disorders
FR2865131B1 (fr) * 2004-01-15 2007-08-24 Gattefosse Ets Sa Utilisation d'un extrait d'acmella oleracea pour son effet botox like dans une composition cosmetique anti-rides
RU2380092C2 (ru) * 2004-01-30 2010-01-27 Кориум Интернэшнл, Инк. Быстро растворяющаяся пленка для доставки активного агента
BRPI0509019A (pt) * 2004-03-22 2007-08-07 Celgene Corp métodos para tratar, prevenir ou controlar um distúrbio ou doença de pele, para tratar, prevenir ou controlar ceratose senil e para tratar ou controlar ceratose, composição farmacêutica, forma de dosagem unitária individual, e, kit
US7228259B2 (en) * 2004-06-30 2007-06-05 Lucent Technologies Inc. Method and apparatus for structure-preserving reduced-order modeling
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
US20060069069A1 (en) * 2004-07-15 2006-03-30 Nanobac Pharmaceuticals, Inc. Methods and compositions for the administration of calcium chelators, bisphosponates and/or citrate compounds and their pharmaceutical uses
EP1771976A4 (en) * 2004-07-22 2011-03-23 Korea Electronics Telecomm SAF SYNCHRONIZATION LAYER PACKAGE STRUCTURE AND SERVER SYSTEM THEREFOR
CA2578250C (en) * 2004-07-26 2013-03-05 Merz Pharma Gmbh & Co. Kgaa Therapeutic composition with a botulinum neurotoxin
CA2518650A1 (en) * 2004-09-10 2006-03-10 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
US20060084353A1 (en) * 2004-10-18 2006-04-20 Wong Tak K Reversible ball having hyper-elastic properties
GB0423554D0 (en) * 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
EP1861112A4 (en) * 2005-03-03 2009-07-22 Revance Therapeutics Inc COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF BOTULINUM TOXINES
US8926991B2 (en) * 2005-06-14 2015-01-06 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US8105611B2 (en) * 2005-06-17 2012-01-31 Allergan, Inc. Treatment of autoimmune disorder with a neurotoxin
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US20070036831A1 (en) * 2005-08-09 2007-02-15 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
AU2006339325A1 (en) * 2005-11-09 2007-09-07 Hormos Medical Ltd. Formulations of fispemifene
US20070148194A1 (en) * 2005-11-29 2007-06-28 Amiji Mansoor M Novel nanoemulsion formulations
US9486408B2 (en) * 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
PT3144013T (pt) * 2005-12-01 2019-02-07 Univ Massachusetts Lowell Nanoemulsões botulínicas
WO2008016664A2 (en) * 2006-08-02 2008-02-07 University Of Massachusetts Lowell Compositions and methods for treating cancer with dacarbazine nanoemulsions
BRPI0719756A2 (pt) * 2006-12-01 2014-01-21 Anterios Inc Nanopartículas de entidades anfifílicas
AU2007353340A1 (en) * 2006-12-01 2008-11-20 Anterios, Inc. Peptide nanoparticles and uses therefor
US8636982B2 (en) * 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US20100137357A1 (en) * 2008-11-26 2010-06-03 Koleng John J Compositions and methods for hyperhidrosis

Also Published As

Publication number Publication date
CA2726836C (en) 2019-06-18
JP2014129426A (ja) 2014-07-10
IL209697B (en) 2018-11-29
CA3042777A1 (en) 2009-12-30
BRPI0914630A2 (pt) 2019-09-24
SG10201608732VA (en) 2016-12-29
AU2019201902A1 (en) 2019-04-11
CA2726836A1 (en) 2009-12-30
AU2009261995A1 (en) 2009-12-30
IL209697A0 (en) 2011-02-28
AU2016203139B2 (en) 2018-12-20
US20160213757A1 (en) 2016-07-28
US20110212157A1 (en) 2011-09-01
KR101848095B1 (ko) 2018-04-11
HK1218874A1 (zh) 2017-03-17
KR20160130519A (ko) 2016-11-11
AU2016203139A1 (en) 2016-06-02
JP2016084366A (ja) 2016-05-19
EP2310000A1 (en) 2011-04-20
KR102080429B1 (ko) 2020-02-21
KR20180135121A (ko) 2018-12-19
WO2009158687A1 (en) 2009-12-30
CN105147608B (zh) 2019-12-10
EP3650017A1 (en) 2020-05-13
MX2010013562A (es) 2011-02-15
EP2310000B1 (en) 2019-09-18
JP2018009026A (ja) 2018-01-18
ES2761664T3 (es) 2020-05-20
AU2019201902B2 (en) 2020-09-10
CN102076333A (zh) 2011-05-25
AU2019201902B8 (en) 2020-09-17
CN105147608A (zh) 2015-12-16
JP2011526302A (ja) 2011-10-06
KR20110033243A (ko) 2011-03-30

Similar Documents

Publication Publication Date Title
MX379265B (es) Aplicacion dérmica de toxina botulínica en nanoemulsiones para usarse en el tratamiento de trastornos de la piel.
WO2012103038A3 (en) Nanoparticle compositions, formulations thereof, and uses therefor
BR112013018919A2 (pt) composições de nanopartículas vazias e seu uso para tratamento de problemas dermatológicos
WO2007100675A3 (en) Collagenase for treating cellulite
MX2007003465A (es) Composicion cosmetica que contiene al menos un hidroxiacido, al menos un mono- o disacarido y al menos una ceramida y procedimientos.
WO2010087964A3 (en) Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof
NZ593343A (en) Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
MY166014A (en) Combination therapy methods for treating proliferative diseases
WO2006108405A3 (de) Nanopartikel-wirkstoff-konjugate
WO2006107825A3 (en) Skin enrichment using coq10 as the delivery system
WO2004112689A8 (en) Transdermal delivery system for cosmetic agents
WO2008045107A3 (en) Botulinum nanoemulsions
WO2009034559A3 (en) Cosmetic process for aesthetic and/or repairing treatment of the skin
WO2009039460A3 (en) Co-administration of pimavanserin with other agents
WO2008089268A3 (en) Methods and compositions for treating conditions associated with infection and/or inflammation
WO2007110422A3 (en) Whey protein vehicle for active agent delivery
WO2011051633A3 (fr) Utilisation d'un extrait de punica granatum pour lutter contre la canitie
MX2011003810A (es) Sistema de nanoparticulas, proceso para la preparacion de las mismas, uso de las mismas, composicion fotoprotectora, proceso para la preparacion de la misma, y metodo de prevencion de enfermedades de la piel.
EA200970154A1 (ru) Косметические или дерматологические препараты, содержащие n-ацетилцистеин
WO2015031971A8 (en) A composition comprising guaçatonga extract and aroeira extract/ use thereof and a method for preventing and/or treating signals caused by skin aging
MX365703B (es) Composicion acuosa rica en aceite y su uso en un metodo de decoloracion o coloracion oxidativa.
MX2009003060A (es) Emulsion.
WO2007100590A3 (en) Methods for treating cellulite
WO2008081095A3 (fr) Utilisation de l'acide gamma-aminobutyrique en tant qu'agent depigmentant
WO2011107433A3 (en) Cosmetic composition based on ellagic acid or a derivative thereof and a bacterial extract